Reduction of circulating beta2-microglobulin level for the treatment of dialysis-related amyloidosis.
about
Human apolipoprotein A-I natural variants: molecular mechanisms underlying amyloidogenic propensityAssociation between plasma Beta-2 microglobulin level and cardiac performance in patients with chronic kidney disease.The relationship between glycemic control, beta2-microglobulin and inflammation in patients on maintenance dialysis treatmentCurrent clinical and pathogenetic understanding of beta2-m amyloidosis in long-term haemodialysis patients.Abeta-2M-amyloidosis and related bone diseases.Association of Beta-2 Microglobulin with Inflammation and Dislipidemia in High-Flux Membrane Hemodialysis Patients.Biomarkers for evaluation of clinical outcomes of hemodiafiltration.Subcutaneous beta2-microglobulin amyloid shoulder nodulesin a long-term hemodialysis patient.Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients.Gastrointestinal Amyloidosis: Approach to Treatment.Examining hemodialyzer membrane performance using proteomic technologies.A new synthetic dialyzer with advanced permselectivity for enhanced low-molecular weight protein removal.Long-term efficacy and safety of the small-sized β2-microglobulin adsorption column for dialysis-related amyloidosis.
P2860
Q28482893-40C2C28F-A487-4712-8F91-119E2616A265Q35089837-53BB52CA-350C-44E1-8B00-AB1C558CE4C9Q35546014-54EDF1A2-34F7-49F7-B692-534B439F6FE2Q35687605-28A38136-E5C1-4E23-95D4-073B42A5EB27Q36406675-C7E173AF-07AA-419F-AD74-08D5CAEE13AFQ37470972-33232FEF-399E-4FBE-A96C-1E396041D185Q38087141-4B6DDBE6-06E9-4163-B5DA-621902D5A5CBQ39863017-91D86362-63E6-414B-AAF4-5195B2DF1649Q43427754-833F41B6-22E4-4F42-A85F-99E5E3AA0859Q44407268-8E86FA5F-39D8-4A40-BCED-F6ADEFF1B11BQ46144079-C0947A42-F03A-4493-AD36-94D33D877431Q47121473-CE56EAAF-11F5-4256-98CA-69CB8D95B312Q47224878-727E73FF-FF4A-4350-B0C2-DC3FCEE3AED9Q48576532-E792E261-BA4B-47C8-8737-C737E242CE0A
P2860
Reduction of circulating beta2-microglobulin level for the treatment of dialysis-related amyloidosis.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Reduction of circulating beta2 ...... dialysis-related amyloidosis.
@ast
Reduction of circulating beta2 ...... dialysis-related amyloidosis.
@en
Reduction of circulating beta2 ...... dialysis-related amyloidosis.
@nl
type
label
Reduction of circulating beta2 ...... dialysis-related amyloidosis.
@ast
Reduction of circulating beta2 ...... dialysis-related amyloidosis.
@en
Reduction of circulating beta2 ...... dialysis-related amyloidosis.
@nl
prefLabel
Reduction of circulating beta2 ...... dialysis-related amyloidosis.
@ast
Reduction of circulating beta2 ...... dialysis-related amyloidosis.
@en
Reduction of circulating beta2 ...... dialysis-related amyloidosis.
@nl
P2093
P356
P1476
Reduction of circulating beta2 ...... dialysis-related amyloidosis.
@en
P2093
P356
10.1093/NDT/16.SUPPL_4.31
P407
P478
16 Suppl 4
P577
2001-01-01T00:00:00Z